Stemline Therapeutics Priced, Nasdaq: STML
Biotech developing treatments that target cancer stem cells and tumor bulk.
Industry: Health Care
First Day Return: +18.0%
Industry: Health Care
STML
Biotech developing treatments that target cancer stem cells and tumor bulk.
| IPO Data | |
|---|---|
| IPO File Date | 04/02/2012 |
| Offer Price | $10.00 |
| Price Range $10.00 - $12.00 | |
| Offer Shares (mm) | 3.3 |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 01/28/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2003 |
| Employees at IPO | 8 |
| Website www.stemline.com | |
IPO News for Stemline Therapeutics
Stemline Therapeutics (STML) Performance
